Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
TARS Stock Chart & Stats
$79.55
$0.07(0.13%)
At close: 4:00 PM EST
$79.55
$0.07(0.13%)
Day’s Range― - ―
52-Week Range$38.51 - $85.25
Previous CloseN/A
Volume127.14K
Average Volume (3M)423.77K
Market Cap
$3.49B
Enterprise Value$2.21B
Total Cash (Recent Filing)$401.84M
Total Debt (Recent Filing)$82.51M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Mar 16, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding42,449,104
10 Day Avg. Volume348,725
30 Day Avg. Volume423,768
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)9.27
Price to Sales (P/S)11.38
P/FCF Ratio-24.61
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue6.04
Enterprise Value/Gross Profit6.81
Enterprise Value/Ebitda-30.49
Forecast
1Y Price Target
$84.60Price Target Upside6.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.47
Revenue Forecast (FY)$443.18M
Bulls Say, Bears Say
Bulls Say
EarningsTarsus Pharmaceuticals reported Q3 earnings with another beat on Xdemvy net sales, marking the company’s eighth consecutive period of growth since approval.
Market PenetrationAnalyst's positive sentiment towards the ongoing XDEMVY launch has led to increased market penetration and revenue estimates due to the expansion of the prescriber base with over 20,000 eye care providers prescribing XDEMVY.
Product AdoptionPrescriber feedback emphasizes XDEMVY as one of the most meaningful therapeutic advances in decades for eye care.
Bears Say
Medicare CoverageAn increase in Medicare patients entering the catastrophic category of coverage, which it expects to continue through year-end.
Operating ExpensesAn increase in operating expenses in the fourth quarter driven primarily by variable costs tied to Xdemvy demand and some additional investments in DTC.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $38.51 and its highest was $85.25 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Tarsus Pharmaceuticals’s market cap is $3.49B.
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is Mar 16, 2026 which is in 95 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.349 by $0.049.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -0.08.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 42,449,104 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.349. Following the earnings report the stock price went down -4.615%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Currently, no hedge funds are holding shares in TARS
Tarsus Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.60 (6.35% Upside)
$84.60 (6.35% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 84.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.02%
12-Months-Change
Fundamentals
Return on Equity
-28.35%
Trailing 12-Months
Asset Growth
42.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS Company Deck
TARS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a strong positive outlook with exceptional product launch performance, robust financial results, and promising pipeline developments. However, challenges remain in managing Medicare-related discounts and rising operational costs.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$84.60
▲(6.35% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.22% Insiders
20.13% Mutual Funds
55.84% Other Institutional Investors
8.25% Public Companies and
Individual Investors